SEC Form 4 · accession 0001127602-18-011451
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Director
Period of report
Mar 9, 2018
Accepted (ET)
Mar 13, 2018 · 6:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $80.72 | Mar 9, 2018 | A | 1,309 | A | — | Mar 9, 2028 | Common Stock | 1,309 | 1,309 | D |
| Restricted Stock UnitF2,F3 | — | Mar 9, 2018 | A | 310 | A | — | — | Common Stock | 310 | 310 | D |
Explanation of responses
- F1Options vest quarterly over the first year of service.
- F2Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F3100% of the restricted stock units will vest in one year on the anniversary date of the grant.